核酸阳性/毒素阴性艰难梭菌感染患者的并发症预测因素与治疗模式
该回顾性队列研究纳入240例PCR阳性/EIA阴性的成人住院患者,发现9.6%发生CDI相关并发症,基线IDSA重症、暴发性结肠炎、发热>38.5℃和PPI使用与并发症风险增加相关;未完成治疗者临床失败率15%,而完成治疗者与PCR+/EIA+患者并发症、死亡率及复发率无差异。
要点
- PCR+/EIA-患者中9.6%发生CDI相关并发症,包括巨结肠、结肠切除和ICU入住。
- 基线IDSA重症、暴发性结肠炎、发热>38.5℃和PPI使用是并发症的独立预测因素。
- 未完成治疗者临床失败率15%,完成治疗者结局与PCR+/EIA+患者相似。
核心结论
- PCR+/EIA-患者中,基线IDSA重症、暴发性结肠炎、发热>38.5℃和PPI使用与CDI相关并发症风险增加独立相关。
- 完成治疗的PCR+/EIA-患者与PCR+/EIA+患者在并发症、60天全因死亡率和复发率上无显著差异。
研究设计与样本
- 回顾性队列研究,纳入所有PCR+/EIA-成人住院患者,共240例。
主要发现
- 23例(9.6%)发生CDI相关并发症,包括2例巨结肠、1例结肠切除和22例ICU入住。
- 多变量logistic回归显示基线IDSA重症(OR 5.84,95%CI 1.88-18.1,P=0.002)、暴发性结肠炎(OR 84.7,95%CI 14.3-500,P<0.001)、发热>38.5℃(OR 4.61,95%CI 1.42-15.0,P=0.011)和PPI使用(OR 3.50,95%CI 1.19-10.3,P=0.023)与并发症风险增加相关。
- 67例未完成治疗的PCR+/EIA-患者中,10例(15%)出现临床失败。
- 完成治疗的PCR+/EIA-患者与112例PCR+/EIA+患者相比,CDI相关并发症(11% vs 13%)、60天全因死亡率(17% vs 18%)和复发率(7% vs 9%)无差异。
关键数值与推荐
- 基线IDSA重症标准:OR 5.84(95%CI 1.88-18.1,P=0.002)。
- 基线暴发性结肠炎:OR 84.7(95%CI 14.3-500,P<0.001)。
- 发热>38.5℃:OR 4.61(95%CI 1.42-15.0,P=0.011)。
- PPI使用:OR 3.50(95%CI 1.19-10.3,P=0.023)。
临床怎么用
- 对PCR+/EIA-患者应评估基线IDSA重症、暴发性结肠炎、发热>38.5℃和PPI使用等预测因素。
- 识别可能为真感染的PCR+/EIA-亚组并给予 targeted 治疗,可能改善结局。
局限性
- 回顾性研究设计可能引入偏倚。
- 未完成治疗组的临床失败率基于67例患者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The addition of toxin enzyme immunoassay (EIA) to nucleic acid amplification tests, including PCR, creates challenges in the diagnosis and management of Clostridioides difficile infection (CDI). There are limited data in large cohorts, with discordant results, that is, PCR-positive/EIA-negative (PCR+/EIA-) results. We conducted a retrospective cohort study on all PCR+/EIA- adult inpatients and assessed CDI-related complications and clinical failure. We identified 240 individuals. Twenty-three (9.6%) patients experienced a CDI-related complication, including 2 cases of megacolon, 1 colectomy, and 22 intensive care unit (ICU) admissions. In multivariable logistic regression analyses, baseline severe disease by Infectious Diseases Society of America (IDSA) criteria (odds ratio [OR], 5.84; 95% confidence interval [CI], 1.88 to 18.1; P = 0.002), baseline fulminant colitis (OR, 84.7; 95% CI, 14.3 to 500; P < 0.001), fever of >38.5°C (OR, 4.61; 95% CI, 1.42 to 15.0; P = 0.011), and proton pump inhibitor (PPI) use (OR, 3.50; 95% CI, 1.19 to 10.3; P = 0.023) were associated with increased odds of CDI-related complications. For 67 PCR+/EIA- patients who did not receive complete treatment, clinical failure was observed in 10 (15%) patients. A comparison of PCR+/EIA- patients who received complete treatment to all 112 PCR+/EIA+ patients showed no differences in CDI-related complications (11% and 13% for PCR+/EIA- and PCR+/EIA+ patients, respectively), 60-day all-cause mortality (17% and 18% for PCR+/EIA- and PCR+/EIA+ patients, respectively), or recurrent CDI (7% and 9% for PCR+/EIA- and PCR+/EIA+ patients, respectively). Predictors of CDI-attributable complications among PCR+/EIA- patients include baseline severe disease by IDSA criteria, baseline fulminant colitis, and fever of >38.5°C. Identifying the subgroup of PCR+/EIA- patients who could have true disease, and therefore allowing them to be targeted for treatment, is critical.
引用
- Miller R, Morillas JA, Brizendine KD, et al. Predictors of Clostridioides difficile Infection-Related Complications and Treatment Patterns among Nucleic Acid Amplification Test-Positive/Toxin Enzyme Immunoassay-Negative Patients. J Clin Microbiol. 2020. PMID: 31896665. doi:10.1128/JCM.01764-19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。